IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
AstraZeneca's IMFINZI plus Amgen's tarlatamab-dlle cut the risk of death by 58% versus IMFINZI alone as 1st-line maintenance in extensive-stage small cell lung cancer, per the Phase III DeLLphi-305 interim analysis (OS HR 0.42, p<0.001). Median overall survival reached 21.1 months with the combination versus 12.7 months for IMFINZI alone — described as the longest benefit ever reported in extensive-stage disease in a Phase III trial. Median PFS was 7.4 vs 1.9 months. Results were presented at ESMO Congress 2026 and simultaneously published in the New England Journal of Medicine; the trial was sponsored by Amgen with partial funding and IMFINZI supplied by AstraZeneca.
Key figures
- Drug Name
- IMFINZI (durvalumab) + tarlatamab-dlle
- Phase Of Trial
- Phase 3
- Orr control pct
- 4.1
- Os hazard ratio
- 0.42
- Pfs hazard ratio
- 0.34
- Orr combination pct
- 26.4
- Patients randomized
- 563
- Os risk death reduction
- 58%
- Median os control months
- 12.7
- Median pfs control months
- 1.9
- Median os combination months
- 21.1
- Median pfs combination months
- 7.4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.